Cargando…
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821305/ https://www.ncbi.nlm.nih.gov/pubmed/36615093 http://dx.doi.org/10.3390/jcm12010291 |
_version_ | 1784865665274871808 |
---|---|
author | Michalet, Morgan Bettaïeb, Ons Khalfi, Samia Ghorbel, Asma Valdenaire, Simon Debuire, Pierre Aillères, Norbert Draghici, Roxana De Méric De Bellefon, Mailys Charissoux, Marie Boisselier, Pierre Demontoy, Sylvain Marguerit, Alexis Cabaillé, Morgane Cantaloube, Marie Keskes, Aïcha Bouhafa, Touria Farcy-Jacquet, Marie-Pierre Fenoglietto, Pascal Azria, David Riou, Olivier |
author_facet | Michalet, Morgan Bettaïeb, Ons Khalfi, Samia Ghorbel, Asma Valdenaire, Simon Debuire, Pierre Aillères, Norbert Draghici, Roxana De Méric De Bellefon, Mailys Charissoux, Marie Boisselier, Pierre Demontoy, Sylvain Marguerit, Alexis Cabaillé, Morgane Cantaloube, Marie Keskes, Aïcha Bouhafa, Touria Farcy-Jacquet, Marie-Pierre Fenoglietto, Pascal Azria, David Riou, Olivier |
author_sort | Michalet, Morgan |
collection | PubMed |
description | Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC), and overall survival (OS). The majority of patients were oligometastatic (58.3%), with 6 right AGM, 5 left AGM and 1 left and right AGM. The prescribed dose was 35 to 50 Gy in 3 to 5 fractions. The median PTV V95% on the initial plan was 95.74%. The median V95% of the PTVoptimized (PTVopt) on the initial plan was 95.26%. Thirty-eight (69%) fractions were adapted. The PTV coverage was significantly improved for adapted plans compared to predicted plans (median PTV V95% increased from 89.85% to 91.17%, p = 0.0478). The plan adaptation also significantly reduced Dmax for the stomach and small intestine. The treatment was well tolerated with no grade > 2 toxicities. With a median follow-up of 15.5 months, the 1–year LC and OS rate were 100% and 91.7%. Six patients (50%) presented a metastatic progression, and one patient (8.3%) died of metastatic evolution during the follow-up. Adaptation of the treatment plan improved the overall dosimetric quality of MRI-guided radiotherapy. A longer follow-up is required to assess late toxicities and clinical results. |
format | Online Article Text |
id | pubmed-9821305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98213052023-01-07 Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results Michalet, Morgan Bettaïeb, Ons Khalfi, Samia Ghorbel, Asma Valdenaire, Simon Debuire, Pierre Aillères, Norbert Draghici, Roxana De Méric De Bellefon, Mailys Charissoux, Marie Boisselier, Pierre Demontoy, Sylvain Marguerit, Alexis Cabaillé, Morgane Cantaloube, Marie Keskes, Aïcha Bouhafa, Touria Farcy-Jacquet, Marie-Pierre Fenoglietto, Pascal Azria, David Riou, Olivier J Clin Med Article Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC), and overall survival (OS). The majority of patients were oligometastatic (58.3%), with 6 right AGM, 5 left AGM and 1 left and right AGM. The prescribed dose was 35 to 50 Gy in 3 to 5 fractions. The median PTV V95% on the initial plan was 95.74%. The median V95% of the PTVoptimized (PTVopt) on the initial plan was 95.26%. Thirty-eight (69%) fractions were adapted. The PTV coverage was significantly improved for adapted plans compared to predicted plans (median PTV V95% increased from 89.85% to 91.17%, p = 0.0478). The plan adaptation also significantly reduced Dmax for the stomach and small intestine. The treatment was well tolerated with no grade > 2 toxicities. With a median follow-up of 15.5 months, the 1–year LC and OS rate were 100% and 91.7%. Six patients (50%) presented a metastatic progression, and one patient (8.3%) died of metastatic evolution during the follow-up. Adaptation of the treatment plan improved the overall dosimetric quality of MRI-guided radiotherapy. A longer follow-up is required to assess late toxicities and clinical results. MDPI 2022-12-30 /pmc/articles/PMC9821305/ /pubmed/36615093 http://dx.doi.org/10.3390/jcm12010291 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Michalet, Morgan Bettaïeb, Ons Khalfi, Samia Ghorbel, Asma Valdenaire, Simon Debuire, Pierre Aillères, Norbert Draghici, Roxana De Méric De Bellefon, Mailys Charissoux, Marie Boisselier, Pierre Demontoy, Sylvain Marguerit, Alexis Cabaillé, Morgane Cantaloube, Marie Keskes, Aïcha Bouhafa, Touria Farcy-Jacquet, Marie-Pierre Fenoglietto, Pascal Azria, David Riou, Olivier Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title | Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title_full | Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title_fullStr | Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title_full_unstemmed | Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title_short | Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results |
title_sort | stereotactic mr-guided radiotherapy for adrenal gland metastases: first clinical results |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821305/ https://www.ncbi.nlm.nih.gov/pubmed/36615093 http://dx.doi.org/10.3390/jcm12010291 |
work_keys_str_mv | AT michaletmorgan stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT bettaiebons stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT khalfisamia stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT ghorbelasma stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT valdenairesimon stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT debuirepierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT ailleresnorbert stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT draghiciroxana stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT demericdebellefonmailys stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT charissouxmarie stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT boisselierpierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT demontoysylvain stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT margueritalexis stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT cabaillemorgane stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT cantaloubemarie stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT keskesaicha stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT bouhafatouria stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT farcyjacquetmariepierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT fenogliettopascal stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT azriadavid stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults AT riouolivier stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults |